Clinical Trial Update: Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating repetitive 24-hour levosimendan infusions for severe systolic heart failure to prevent rehospitalizations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systolic Heart Failure

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Collegium Medicum w Bydgoszczy | Conditions: Systolic Heart Failure | Phase 4 | Status: UNKNOWN